Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-08-07
2007-08-07
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C435S069100
Reexamination Certificate
active
10978202
ABSTRACT:
Peptides and methods of their use for inhibiting drug and radiation-therapy resistance in cancerous cells in which efficacy of chemotherapy and/or radiotherapy of a patient is enhanced by administration of an effective amount of a peptide that inhibits cell adhesion mediated drug resistance (CAM-DR). Preferably, the peptide comprises D-amino acids having the sequence:in-line-formulae description="In-line Formulae" end="lead"?kmviywkag (RZ-3)in-line-formulae description="In-line Formulae" end="tail"?or is a variant or modified version thereof. The peptide is preferably administered to the patient prior to chemotherapy and/or radiation therapy. Inhibition of cell adhesion mediated drug resistance (CAM-DR) by RZ-3 in multiple myeloma cells is disclosed.
REFERENCES:
patent: 6812003 (2004-11-01), Dalton et al.
patent: 2003/0004140 (2003-01-01), Dalton et al.
patent: WO 01/64207 (2001-09-01), None
patent: WO 01/64714 (2001-09-01), None
U.S. Appl. No. 09/795,474, filed Mar. 1, 2001, Dalton et al, (patent application).
Damiano, J. et al. “Cell Adhesion Mediated Drug Resitance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines”Blood, 1999, 93(5):1658-1667.
Dermer “Another Anniversary for the war on cancer” 1994, Biotechnology, vol. 12, pp. 320.
Deroock, I. et al. “Synthetic Peptides Inhibit Adhesion on Human Tumor Cells to Extracellular Matrix Proteins”Cancer Research, 2001, 61:3308-3313.
Hazlehurst, L.A. et al. “Adhesion to Fibronectin via β1 Integrins Regulates p27kp1Levels and Contributes to Cell Adhesion Mediated Drug Resistance (CAM-DR)”Oncogene, 2000, pp. 4319-4327.
Pennington, M. et al. “The Use of a Combinatorial Library Method to Isolate Human Tumor Cell Adhesion Peptides”,Molecular Diversity, 1996, 2:19-28.
Voskoglou-Nomikos, T. et al. “Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models”Clinical Cancer Research, 2003, 9(11):4227-4239.
Hiraga, T. et al. “Combined treatment with bisphosphonates and oral UFT inhibits bone and soft organ metastases and prolongs survival”J. Bone and Mineral Res., 1999, 14(1):S188, abstract.
Ausili-Cefaro, G. et al. “Radiation therapy vs radiation therapy + pamidronate (Aredia®) in elderly patients with breast cancer and lytic bone metastases: A grog-gioger randomized clinical trial”RAYS, 1999, 24:49-52.
Desikan, K. et al. “Recent advances in the treatment of multiple myeloma”,Curr. Opin. Hematol., 1999, 6:216-221.
Kennedy, M.J. “Metastatic breast cancer”Curr. Opin. Oncology, 1996, 8:485-490.
Cress Anne E.
Dalton William S.
Damiano Jason S.
Saliwanchik Lloyd & Saliwanchik
Teller Roy
Tsang Cecilia J.
University of South Florida
LandOfFree
Compounds and methods for modulating cell-adhesion mediated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for modulating cell-adhesion mediated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for modulating cell-adhesion mediated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3870466